SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 8-K - Current report:
SEC Accession No. 0001193125-24-038473
Filing Date
2024-02-16
Accepted
2024-02-16 16:06:02
Documents
17
Period of Report
2024-02-14
Items
Item 1.01: Entry into a Material Definitive Agreement
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 8-K d780024d8k.htm   iXBRL 8-K 29405
2 EX-1.1 d780024dex11.htm EX-1.1 236067
3 EX-5.1 d780024dex51.htm EX-5.1 7970
7 GRAPHIC g780024g0215083623153.jpg GRAPHIC 2656
  Complete submission text file 0001193125-24-038473.txt   467135

Data Files

Seq Description Document Type Size
4 XBRL TAXONOMY EXTENSION SCHEMA lrmr-20240214.xsd EX-101.SCH 2856
5 XBRL TAXONOMY EXTENSION LABEL LINKBASE lrmr-20240214_lab.xml EX-101.LAB 17994
6 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE lrmr-20240214_pre.xml EX-101.PRE 11265
18 EXTRACTED XBRL INSTANCE DOCUMENT d780024d8k_htm.xml XML 3646
Mailing Address THREE BALA PLAZA EAST. SUITE 506 BALA CYNWYD PA 19004
Business Address THREE BALA PLAZA EAST. SUITE 506 BALA CYNWYD PA 19004 844-511-9056
Larimar Therapeutics, Inc. (Filer) CIK: 0001374690 (see all company filings)

IRS No.: 203857670 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-36510 | Film No.: 24648343
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)